Bactiguard appoints Christine Lind as new CEO
The Board of Directors of Bactiguard Holding AB (publ.) has appointed Christine Lind as new CEO. Christine brings broad strategic and operational experience from more than 25 years in the healthcare sector. Previous assignments encompass positions in Swedish listed companies such as Mendus AB, XSPRAY PHARMA AB, and Medivir AB as well as senior advisory roles. Prior to that, Christine spent a decade as an investment banker at Merrill Lynch. She joins Bactiguard at the beginning of May and assumes the role as CEO on 14 May 2024 in connection with the Annual General Meeting.
“We are delighted to welcome Christine Lind to Bactiguard. With her extensive expertise in life sciences, coupled with international, strategic, and commercial skills, she brings valuable insights to us. As Bactiguard has embraced a sharpened license focused strategy, the criteria for a future CEO have evolved. Christine’s proven track record of strategic shifts, driving change and achieving profitable growth, and her background in the financial markets, both as CEO and investment banker, positions her perfectly for Bactiguard. Furthermore, her reputation as a modern and respected leader, and strong team player will be instrumental on our transformation journey. Christine’s appointment is pivotal as we transition Bactiguard into a global knowledge and specialist organization, with a steadfast focus on delivering on our bold financial targets,” says Bactiguard’s Chairperson Christian Kinch.
Christian Kinch continues: “I would also like to thank Thomas von Koch, on behalf of the entire Board of Directors, for his dedicated work and exceptional leadership during a critical time for Bactiguard. Several challenging but crucial strategic decisions have been taken under his leadership and he has kick-started the transformation work which is now well underway. Thomas has showed us what responsible ownership means and he will hand over the CEO responsibilities to Christine in a structured and coordinated manner, having the very best interest of Bactiguard and our stakeholders in mind.”
“Working in businesses with a greater purpose has been a red thread across my career. Joining Bactiguard presents exactly the kind of opportunity I am thrilled to pursue. Together with the team and Board of Directors at Bactiguard, and in close collaboration with license partners across the world, we have the potential to revolutionize the global standard of care, thanks to Bactiguard’s unique infection prevention technology, and simultaneously make the world a healthier place. Equally important is my task to steer Bactiguard to profitability and achieve sustainable growth. I am excited to lead Bactiguard into the future and deliver on our important mission," comments Christine Lind, Bactiguard’s upcoming CEO.
About Christine Lind
Christine Lind was born in 1974 in the US and has lived in Sweden since 2015. She holds a BSc in Finance & Information Systems from New York University and an MBA from Columbia Business School. Throughout her career, she has held CEO and executive level business development and strategy positions at biotech companies, including BioArctic AB, Medivir AB and LifeCell Corporation. Christine also spent a decade as an investment banker at Merrill Lynch in New York, advising biotech and pharma companies on licensing, M&A, and financing. She comes most recently from a role as Senior Vice President Corporate Development at SSI Strategy/NDA Group AB.
This is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2024-02-07, at 18:15 CET.
For further information, please contact:
Nina Nornholm, Head of Communication & Investor Relations +46 708 550 356
Year-end report 2023 presentation
As a reminder, Bactiguard Holding AB (publ) publishes its year-end report 2023 on February 8, 2024, at 08:00 CET. In connection with this, an audiocast will be hosted for investors, analysts, and media at 11:00 CET where interim CEO Thomas von Koch and CFO Patrick Back will be available for questions. The report and a presentation will be available on www.bactiguard.com
About Bactiguard
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention technology and solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products.
Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.
Read more about Bactiguard: www.bactiguard.com
Follow Bactiguard on LinkedIn
